Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

The survival of most patients with acute myelogenous leukemia (AML) remains poor, and novel therapeutic approaches are needed to improve outcomes. Given that the fraction of AML with mutated p53 is small (∼ 10%), it appears rational to study MDM2 inhibitors as therapy for AML. Here, we report result...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Long, Jianting, Parkin, Brian, Ouillette, Peter, Bixby, Dale, Shedden, Kerby, Erba, Harry, Wang, Shaomeng, Malek, Sami N.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2010
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2904583/
https://ncbi.nlm.nih.gov/pubmed/20404136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-01-261628
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi